✦ LIBER ✦
Sa1270 Can We Increase the Dose Interval of Infliximab to 10 Weeks Without Risking Loss of Response in Patients With Crohn's Disease? Prospective, Single-Center Pilot Study Based on Successive Measurements of Fecal Calprotectin
✍ Scribed by Mantzaris, Gerassimos J.; Karatzas, Pantelis; Kyriakos, Nikolaos; Archavlis, Emmanuel J.; Papamichael, Konstantinos; Tzannetakou, Xanthippi; Internos, Iosif; Anastasiadis, Stelios; Tsironikos, Dimitrios; Drougas, Ioannis
- Book ID
- 122253086
- Publisher
- Elsevier Science
- Year
- 2014
- Tongue
- English
- Weight
- 50 KB
- Volume
- 146
- Category
- Article
- ISSN
- 0016-5085
No coin nor oath required. For personal study only.